Comparison of work productivity losses in the United States among employees with COVID-19 at high-risk of severe disease who were untreated or treated with nirmatrelvir/ritonavir

作者：M. Fernandez, Brenna L. Brady, Kristin Evans, Gurinder Sidhu, Paul Cislo, Frank R. Ernst, Joseph C. Cappelleri, Mohammad A. Chaudhary, Emmanuel F. Drabo, Ruth Mokgokong · 发表于：Journal of Medical Economics · 年份：2025 · DOI：10.1080/13696998.2025.2601454 · 被引用次数：1 · 研究领域：SARS-CoV-2 and COVID-19 Research、COVID-19 Clinical Research Studies、Long-Term Effects of COVID-19

Aim Nirmatrelvir-ritonavir (NMV/r; Paxlovid) treatment reduces COVID-19-related morbidity, mortality, and direct healthcare burdens. To investigate the potential impact of NMV/r on indirect disease burdens, we compared workplace productivity between employees diagnosed with COVID-19 who were and were not treated with NMV/r.Methods Adult employees with COVID-19 at high-risk of severe disease were identified in the Merative MarketScan Health and Productivity Management Database. Index date was the first COVID-19 diagnosis on or after 12/16/2021; employees were followed over a six-month pre-period and ≥30-day post-period. Individuals treated with NMV/r (claim within 5 days of index) were exactly matched 1:1 to untreated employees based on age, sex, index quarter, Charlson Comorbidity Index, and pre-period acute care visits. Lost workdays per-patient-per-month (PPPM) and associated estimated indirect costs due to absence, short-term disability (STD), or long-term disability (LTD) were compared between matched treated and untreated cohorts over the variable post-period using paired t-tests or Chi-squared tests and two-part hurdle models.Results Treated and untreated absence, STD, and LTD analyses included n = 1,909, n = 20,065, and n = 20,318 employees respectively. NMV/r treatment was associated with significantly fewer lost workdays PPPM from absence (mean[SD]: 2.06[2.37] vs. 2.22[2.49], p < 0.05), STD (0.41[2.17] vs. 0.52[2.42], p < 0.001), and LTD (0.02[0.061] vs. 0.04[0.79], ...